ghk-cu uses Peptide for Skin & Hair GHK-Cu - Peptide for Collagen,

The peptide also increases NAD+ levels, which activate the SIRT1 gene

Contraindications and Precautions Avoid GHK-Cu research if: Diagnosed copper metabolism disorders (Wilson's disease, Menkes disease) Current copper overload or elevated serum copper levels Active cancer (GHK-Cu's growth promoting effects are theoretical concern) Pregnancy or breastfeeding (insufficient safety data) Severe kidney or liver disease (impaired copper metabolism) Use caution with: Hemochromatosis or iron overload conditions Blood clotting disorders (copper affects coagulation factors) Autoimmune conditions (immune modulating effects) Concurrent use of copper supplements (avoid excess copper intake) Monitoring and Risk Mitigation Responsible research protocols include: Baseline Testing: Serum copper and ceruloplasmin levels before starting Liver function tests (copper affects hepatic function) Complete blood count Ongoing Monitoring: Injection site inspection for infections or reactions Periodic copper level checks during extended use (every 3 to 6 months) Liver enzymes if using higher doses long term Discontinue if unusual symptoms develop Red Flags Requiring Immediate Cessation: Severe injection site infection (warmth, spreading redness, pus) Systemic allergic reactions (hives, difficulty breathing, swelling) Significant nausea, vomiting, or abdominal pain Jaundice (yellowing of skin or eyes) Unexplained bleeding or bruising Drug Interactions GHK-Cu may interact with: Copper supplements: Avoid concurrent use to prevent excess copper Zinc supplements: High zinc intake antagonizes copper absorption Penicillamine: Chelates copper, may reduce GHK-Cu effects Blood thinners: Theoretical interaction through copper's effects on clotting factors Always disclose all supplements and medications when consulting healthcare professionals about peptide research

Add 3mL of bacteriostatic water to a 30mg vial

10.1093/brain/awm276 Brain 11 BhadriN.RazdanR.GoswamiS

Coprecipitation refers to the process in which bioactive peptides or proteins are loaded in situ within MOFs during synthesis, thereby forming a shell that inhibits the release of these bioactive agents